486 related articles for article (PubMed ID: 32279088)
1. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibition in UV-associated angiosarcoma preclinical models.
Weidema ME; Desar IME; Hillebrandt-Roeffen MHS; van Erp AEM; Masuzawa M; ; Flucke UE; van der Graaf WTA; Versleijen-Jonkers YMH
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2579-2590. PubMed ID: 34085099
[TBL] [Abstract][Full Text] [Related]
3. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Lok BH; Gardner EE; Schneeberger VE; Ni A; Desmeules P; Rekhtman N; de Stanchina E; Teicher BA; Riaz N; Powell SN; Poirier JT; Rudin CM
Clin Cancer Res; 2017 Jan; 23(2):523-535. PubMed ID: 27440269
[TBL] [Abstract][Full Text] [Related]
4. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
Murai J; Feng Y; Yu GK; Ru Y; Tang SW; Shen Y; Pommier Y
Oncotarget; 2016 Nov; 7(47):76534-76550. PubMed ID: 27708213
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
6. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP
Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275
[TBL] [Abstract][Full Text] [Related]
7. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
8. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Pignochino Y; Capozzi F; D'Ambrosio L; Dell'Aglio C; Basiricò M; Canta M; Lorenzato A; Vignolo Lutati F; Aliberti S; Palesandro E; Boccone P; Galizia D; Miano S; Chiabotto G; Napione L; Gammaitoni L; Sangiolo D; Benassi MS; Pasini B; Chiorino G; Aglietta M; Grignani G
Mol Cancer; 2017 Apr; 16(1):86. PubMed ID: 28454547
[TBL] [Abstract][Full Text] [Related]
9. Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer.
Tanaka M; Sasaki M; Suzuki T; Nishie H; Kataoka H
Biochem Biophys Res Commun; 2021 Feb; 539():1-7. PubMed ID: 33388624
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
[TBL] [Abstract][Full Text] [Related]
11. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
13. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
[TBL] [Abstract][Full Text] [Related]
14. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.
Bianchi A; Lopez S; Altwerger G; Bellone S; Bonazzoli E; Zammataro L; Manzano A; Manara P; Perrone E; Zeybek B; Han C; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Newberg JY; Pavlick DC; Elvin J; Frampton GM; Schwartz PE; Santin AD
Gynecol Oncol; 2019 Oct; 155(1):144-150. PubMed ID: 31434613
[TBL] [Abstract][Full Text] [Related]
15. The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.
Park HJ; Bae JS; Kim KM; Moon YJ; Park SH; Ha SH; Hussein UK; Zhang Z; Park HS; Park BH; Moon WS; Kim JR; Jang KY
J Exp Clin Cancer Res; 2018 May; 37(1):107. PubMed ID: 29784019
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.
Norris RE; Adamson PC; Nguyen VT; Fox E
Pediatr Blood Cancer; 2014 Jan; 61(1):145-50. PubMed ID: 24038812
[TBL] [Abstract][Full Text] [Related]
17. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
[TBL] [Abstract][Full Text] [Related]
18. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
[TBL] [Abstract][Full Text] [Related]
19. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells.
Liu C; Gross N; Li Y; Li G; Wang Z; Zhong S; Li Y; Hu G
J Cell Mol Med; 2020 Feb; 24(4):2444-2450. PubMed ID: 31957270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
